Clinical Trial Update: PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating PI3K inhibitors for relapsed/refractory indolent T/NK-cell lymphomas and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Large Granular Lymphocytic Leukemia
• T-cell Large Granular Leukemia
• T-cell Lymphoma

Drugs mentioned

• PI3K inhibitors (PI3K inhibitors)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Status: RECRUITING